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Abstract
Background: Tendinopathies are tendon conditions associated with degeneration and disorganization of the matrix
collagen fibers, tendon cells apoptosis and inflammation through up-regulation of proinflammatory cytokines, matrix
metalloproteinase (MMP) expression, and prostaglandin E2 (PGE2) production. Currently, the pharmacological treatment
is mainly based on non-steroidal anti-inflammatory drugs (NSAIDs) use and corticosteroid injections, which both can
lead to numerous side effects for patients. TOL19-001 is a diet supplementary composed mostly of spirulina and
glucosamine sulfate whose antioxidant properties could be helpful to treat tendinopathies while avoiding taking
NSAIDs. In this study we developed an in vitro model of tendinopathy in order to evaluate the therapeutic potential
of TOL19-001.
Methods: Tendon cells were cultured on monolayer and treated with interleukin-1β (IL-1β) or ciprofloxacin (CIP), and
then, MMPs, PGE2 and collagen expression was evaluated by RT-PCR or Elisa. In addition, a cotreatment with increased
doses of TOL19-001 was done. Toxicity of TOL19-001 was evaluated using a metabolic activity assay.
Results: This study demonstrates that IL-1β mimics some aspects of tendinopathies with PGE2 induction, MMP
expression (mostly MMP1 and MMP3), and increases of type III/I collagen ratio. CIP, meanwhile, leads to an increase of
MMP2 and p65 mRNA, whereas it reduces TIMP1 expression. Scleraxis expression was also increased by CIP whereas it
was decreased by IL-1β treatment. Besides, TOL19-001 cotreatment suppresses tendon cell inflammation in vitro,
marked by the downregulation of PGE2, MMPs and type III collagen in IL-1β stimulated-cells. TOL19-001 also represses
CIP induced-changes.
Conclusions: These findings indicate that TOL19-001 exerts anti-inflammatory effects on tendon cells, which might
explain why TOL19-001 diet may improve tendon function in patients with tendon injury. Future research is required
to determine TOL19-001 effect on injured or overused tendons in vivo.
Keywords: Cytokines, Tendons, Tendinopathy, Spirulina, Quinolone, Ciprofloxacin, Interleukin-1, Matrix
metalloproteinases, Inflammation, Dietary supplements, Humans, In vitro model
Background
A tendon is a fibrous connective tissue which attaches
muscle to bone, and transmits force producing movements.
Tendons also function to stabilize joints and absorb large
shocks, protecting muscles from damage. The major ele-
ments of the extracellular matrix are collagen fibers which
represent about 65 to 80 % dry weight of tendon. These
collagen fibers, which are composed of type I collagen
(95 % of collagens) [1], and of some minor collagens
(collagen III, V and X), provide the tendons with
strength to withstand high loads. Proteoglycans, such as
decorin, glycoproteins and elastin also composed ten-
don matrix [1, 2]. These specific matrix components
give tendon its resilience and biomechanical stability.
The cellular component is represented by tenoblasts and
tenocytes, which are arranged in parallel rows between the
collagen fibers. Tenoblasts are immature spindle-shaped
tendon cells, containing abundant cytoplasmic organelles,
reflecting their high metabolic activity. As they age, teno-
blasts become elongated and transform into tenocytes. To-
gether, tenoblasts and tenocytes account for 90 to 95 % of
the cellular elements of tendons. The remaining cellular
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elements consist of chondrocytes, synovial cells and endo-
thelial cells [3]. Tenocytes have a low mitotic activity and
are poorly vascularized. Consequently, the metabolic rate of
tendons is relatively limited; oxygen consumption is 7.5
times lower than that of skeletal muscle and the turnover
time for tendon collagen varies from 50 to 100 days [4]. So,
damaged tendons are difficult to regenerate [5], and its re-
covery after injury takes time.
Historically, chronic pain referring to a symptomatic ten-
don was called “tendinitis”, implying inflammation as a
central pathological process. The more generically term
“tendinopathy” (TP) is now currently preferred [3, 6].
These tendon disorders are common and account for a
high proportion of referrals to rheumatologists and ortho-
pedic surgeons [7]. Several factors have been implicated in
TP pathogenesis, most of which may cause localized in-
flammatory reactions and also microdegeneration. Genetic
background and age may also play a role. Additionally, the
use of several drugs has been associated with TPs: the asso-
ciation has been proven for fluroquinolone antibiotics [8],
whereas the responsibility of statins [9], oral contraceptives
and locally injected corticosteroids [10, 11] is still debated.
Tendon healing occurs in three distinct but partially
overlapping phases [12]. The acute inflammatory phase
lasts for up to 3 to 7 days after injury. During this phase,
inflammatory agents such as interleukin-1β (IL-1β) are
produced by macrophages and other inflammatory cells
at the injured site. Then, the proliferation phase lasts
between 5 and 21 days. Tenocytes produce collagen,
which gradually increases the mechanical strength of the
tendon, so that loading can lead to elastic deformation.
The last phase is the maturation and remodeling phase
and it can take place for up to a year. The cross-linking
among collagen fibers increases and the tensile strength,
elasticity and structure of the tendon are improved.
The healing process [13] is primarily mediated by matrix
metalloproteinases (MMPs) and metalloproteinases with
thrombospondin motifs (ADAMTs) [14] and their tissue
inhibitors (TIMPs) [15]. These enzymes participate in
both collagen degradation and remodeling [14]. In
addition, during TP, changes in rates of collagen were
observed, including an increase in the proportion of colla-
gen type III compared to collagen type I. Wounding and
inflammation also provoke the release of growth factors
and cytokines from platelets, polymorphonuclear leuko-
cytes, macrophages and other inflammatory cells. These
growth factors induce neovascularization and stimulate
fibroblasts and tenocyte proliferation and synthesis of
collagen [16]. PGE2 could also be involved in the
healing process. PGE2 is a potent inhibitor of type I
collagen synthesis [17–19] and it has recently been
shown that PGE2 has catabolic effects on tendon struc-
ture, decreasing proliferation and collagen production
in human patellar tendon fibroblasts [20].
Since tendon injuries are common in adults, and require
more than 300,000 surgeries of tendons each year in the
U.S. [21], it is important to identify substances that can im-
prove the treatment or prevented tendon injuries. Non-
steroidal anti-inflammatory drugs and corticosteroids are
commonly prescribed to minimize inflammation and sub-
sequent damage to tissue integrity [22]. They may be bene-
ficial for pain and function in the early phases of disease,
but are usually ineffective later [23, 24], and associated
with numerous side effects including inhibitory effects on
proteoglycan synthesis and cell proliferation [25]. There-
fore, investigation continues for safer and more selective
pharmaco-therapies for tendinopathies. Preliminary studies
utilizing Platelet-Rich-Plasma (PRP) [26], anakinra (an
interleukin-1 antagonist) [26] or apronitin (a MMP-
inhibitor) [28] have produced encouraging results, suggest-
ing that substances targeting IL-1β or inhibiting MMPs
may be useful. Here, we propose that the association of
spirulina, glucosamine sulfate, ginseng, selenium, sillicium,
iron, vitamin E and zinc (TOL19-001, marketed as Cica-
tendon®, LABRHA Laboratory, Lyon, France) may have a
beneficial effect on tendon healing and repair.
In this study, we developed two original models to
investigate in vitro effects of drugs on a heterogeneous
population of human resident tendon cells in adherent
monolayer culture, and showed that TOL19-001
efficiency reduces inflammation and MMP expression.
Methods
Reagents
Reagents were supplied by Invitrogen (Fisher Bioblock
Scientific, Illkirch, France) unless otherwise noted. IL-1β
(Sigma-Aldrich, St. Quentin Fallavier, France) was resus-
pended in phosphate buffered saline (PBS) with BSA.
Ciprofloxacin (CIP) was provided by Fresenius Kabi
(Sèvres, France). Oligonucleotides were supplied by
Eurogentec (Angers, France). TOL19-001 (Cicatendon®,
Labhra, Lyon, France) was resuspended in PBS.
Tendon cell culture
Tendons from the pyramidal muscle were obtained from
patients undergoing arthroscopic surgery. All donors signed
agreement forms before surgery, according to local legis-
lations (agreement #A13-D46-VOL.19 obtained from local
ethical committee, “Comité de Protection des Personnes
Nord Ouest III”). Human resident tendon cells were isolated
by washing several times tendon samples with phosphate
buffered saline (PBS), dissection into small pieces and incuba-
tion with 2 % collagenase type II in DMEM supplemented
with 10 % fetal calf serum (FCS) overnight at 37 °C. The
digested material was then placed in a tissue culture flask and
cultured in DMEM supplemented with 10 % FCS and anti-
biotics. Cells were incubated at 37 °C, 95 % humidity and 5 %
carbon dioxide with a change of medium every 2–3 days.
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Experimental design
In all experiments, tendon cells after one passage were
used to prevent their dedifferentiation.
Tendon cells were treated at confluency with IL-1β or
CIP in the presence or not of TOL19-001 for 48 h. Then,
different analysis were performed on cells or culture
medium.
RNA Extraction and real-time reverse transcription–
Polymerase chain reaction
Total RNA from primary tendon cell cultures were ex-
tracted using Trizol® Reagent (Life Technologies, #15596-
018) [27, 28]. After extraction, 1 μg of DNase-I–treated
RNA was reverse transcribed into cDNA in the presence of
oligodT and Moloney murine leukemia virus reverse tran-
scriptase. The reaction was carried out at 37 °C for 1 h
followed by a further 10-min step at 95 °C. Amplification of
the generated cDNA was performed by real-time PCR in an
Applied Biosystems SDS7000 apparatus with appropriate
primers designed with Primer Express software. The rela-
tive mRNA level was calculated with the 2–ΔΔCT method.
WST1 assay
Cytotoxicity was evaluated by tetrazolium colorimetric
WST1 assay (Product No 05015944001, Roche Diagnostics,
Meylan, France) [29, 30]. Tetrazolium salts are cleaved to
formazan by the succinate-tetrazolium reductase system
(EC 1.3.99.1) which belongs to the respiratory chain of the
mitochondria, and is only active in metabolically intact
cells. Therefore, the amount of formazan dye formed
(which can be quantitated with a scanning multi-well
spectrophotometer) directly correlates to the number of
metabolically active cells in the culture.
Tendon cells (undergoing one passage) were plated into
96-well microtiter plates. At 70 % confluence, cells were
incubated with CIP (100 μg/ml) or IL-1β (1 ng/ml). One
hour before the end of incubation, 10 μl of WST1 solution
were added to all wells. Optical density was measured on
a spectrophotometer plate reader (1420 Multilabel Coun-
ter, Perkin Elmer) at 450 nm. A well without cells contain-
ing complete medium and WST1 only acted as blanks.
Elisa
PGE2 and MMPs released into conditioned media was
quantified using commercially available enzyme immuno-
assay kit (R&D Systems). Absorbance was determined at
450 nm with a wavelength correction set at 540 nm.
Statistical analysis
Three different experiments were performed. The values
are means ± standard deviation and the significance of
differences was calculated with Student’s t test.
Results
This study was undertaken to investigate the effect of
TOL19-001® in human tendon cells in two in vitro models
of tendinopathies. However, such models do not currently
exist. Since tendon overuse injuries and tendinopathies
are accompanied by inflammation through up-regulation
of proinflammatory cytokines, matrix metalloproteinase
(MMP) expression, and prostaglandin E2 (PGE2) produc-
tion, which could initiate the degradation and remodeling
of tendons [31, 32], we tried to reproduce these changes
in tendon cell culture. Two approaches were tested: the
first one was a treatment with a fluoroquinolone anti-
biotic, called ciprofloxacin (CIP); the second one consists
to treat cells with a proinflammatory cytokine, IL-1β.
CIP and IL-1β differently induced MMP expression in
tendon cells
First, we analyzed the induction of MMPs (MMP1, 2, 3) by
CIP and IL-1β (Figure 1). Tendon cells (at passage 1) were
treated with IL-1β (1 ng/ml) or CIP (100 μg/ml) for 48 h. By
RT-PCR and Elisa, we found that IL-1β strongly increased
MMP1, MMP2 and MMP3 mRNA level, and release in
medium. The effect on MMP2 was more moderated com-
pared to MMP1 and MMP3. CIP, meanwhile, induced a
slight increase of MMP1, MMP2 and MMP3 mRNA levels.
The induction of MMP2 was more important compared to
other MMPs, and similar to this obtained with IL-1β treat-
ment. However, no significant effect on MMP release in
medium was observed after CIP treatment.
Furthermore, we investigated the effect of IL-1β and
CIP on TIMP1 expression, and showed that 48 h-treat-
ment with IL-1β increased TIMP1 mRNA level, whereas
CIP reduced it.
CIP, but not IL-1β increased p65 mRNA expression
Since it is known that MMPs are regulated, in part, by
NFκB pathway, we hypothesized that IL-1β and CIP may
activate this signaling pathway in tendons cells. Insofar
as we have previously observed that IL-1β regulates
NFκB signaling in chondrocytes, in part, by increasing
mRNA expression of the NFκB subunit p65, we postu-
lated that, in tendon cells, IL-1β and CIP may also
upregulate p65. Surprisingly, IL-1β (1 ng/ml) did not in-
duce an increased p65 mRNA level in tendon cells after
48 h-treatment (Fig. 2a). However, CIP increased its ex-
pression. This suggests that CIP and IL-1β have different
mechanisms of action.
IL-1β, but not CIP, induced PGE2 in tendon cells
We also investigated the effect of IL-1β and CIP treat-
ment on PGE2 expression (Fig. 2b). As for MMPs, we
found a differential response of tendon cells to treat-
ments. In our culture conditions, only IL-1β was able to
significantly induce PGE2 release by tendon cells.
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IL-1β downregulated type I collagen and scleraxis,
whereas it upregulated type III collagen
Furthermore, we examined whether CIP or IL-1β treat-
ment modify matrix gene expression (Fig. 3a and b). We
focused on type I and type III collagens, the major compo-
nents of tendon matrix. Interestingly, we found that IL-1β
treatment reduced type I collagen mRNA level, whereas it
increased type III collagen expression. In contrast, we
could not find a significant effect of CIP.
It is known that type I collagen is regulated in part by
scleraxis in tenocytes. Therefore, we investigated the effect
of IL-1β on scleraxis expression (Fig. 3c), and showed that
IL-1β down-regulated scleraxis mRNA that could explained
the reduction of type I collagen by IL-1β.
TOL19-001® is not toxic for tendon cells
Tendon cells treated with TOL19-001 (0.5 – 3 μg/ml of
spirulina) showed no sign of cytotoxic effects or any
Fig. 1 Effect of CIP and IL-1β on MMPs and TIMP-1 expression. Tendon cells (have been incubated with CIP (100 μg/ml) or IL-1β (1 ng/ml) for
48 h. Next, MMP1, MMP2 and MMP3 mRNA levels were determined by RT-PCR (a), and MMP release by ELISA (b). TIMP1 mRNA expression was
also determined by RT-PCR (c). Histograms represent mean values from 3 independent experiments ± SEM
Fig. 2 Effect of CIP and IL-1β on p65 mRNA level and PGE2 release. Tendon cells were treated as Fig. 1, and p65 mRNA level (a) and PGE2 release
(b) were determined by RT-PCR and ELISA, respectively. Histograms represent mean values from 3 independent experiments ± SEM
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negative effects on cell viability (data not shown) at the
light microscopic. In addition, treatment did not affect
cell proliferation as shown by Wst1 assay (Fig. 4).
TOL19-001® reduced PGE2 and MMP expression in IL-1β
stimulated- tendon cells
Co-treatment with TOL19-001 reduced the effects of IL-1β.
Indeed, at mRNA level, TOL19-001, (used at 1.5 μg/ml of
spirulina), significantly inhibited the induction of MMP1,
MMP2 and MMP3 (by about 40 %) (Fig. 5a). These effects
were also found when we analyzed MMP release in
medium, but were less important (Fig. 5b). In addition,
TOL19-001 impaired PGE2 release in IL-1β stimulated-
tendon cells (Fig. 5B). Interestingly, co-treatment of tendon
cells with TOL19-001 also reduces type III collagen expres-
sion in IL-1β treated-cells (Fig. 5c).
TOL19-001® decreased MMP2 and p65 expression in CIP
stimulated-tendon cells
We, also, examined whether TOL19-001 was also able to
counteract CIP effects on tendon cells. TOL19-001 co-
treatment reduced MMP2 and p65 mRNA expression,
Fig. 3 Effect of CIP and IL-1β on type I and III collagen and scleraxis mRNA level. Tendon cells were treated as Fig. 1, and type I and III collagen
(a, b) and scleraxis (c) mRNA expression was evaluated by RT-PCR. Histograms represent mean values from 3 independent experiments ± SEM
Fig. 4 Effect of TOL19-001® on metabolic activity of tendon cells.
Tendon cells (at passage 1) have been incubated in the presence of
TOL19-001® (dose equivalent to 0.5 to 3 μg/ml of spirulina) for 48 h.
Then, metabolic activity was evaluated by Wst1 assay. Values were
normalized to OD from untreated cells. Histograms represent mean
values from 3 independent experiments ± SEM
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whereas it increased that of TIMP1 in CIP stimulated-
tendon cells (Fig. 6).
These results showed that TOL19-001 counteracts
most of CIP and IL-1β induced-effects on tendon cells.
Discussion
A major difficulty to identify efficient treatments against
TPs is the absence of models easily usable in laboratory. In-
deed, there is currently no in vitro nor in vivo model cap-
able of mimicking all the conditions of these pathologies.
Here, we used two different condition cultures able to
induce some modifications comparable to human TP
pathologies, which are accompanied by inflammation and
degradation of the tendon extracellular matrix.
The first model was a treatment of monolayer culture
of tendon cells with CIP, a fluoroquinolone antibiotic.
This family of drugs is, indeed, known to induce tendon
lesions in vivo [33–40] by causing matrix disruption,
inflammation, and degenerative changes of tenocytes
[37, 41]. In this study, we showed that CIP affects
Fig. 5 Effect of TOL19-001® in IL-1β stimulated-tendon cells. Tendon cells have been treated with IL-1β (1 ng/ml) and TOL19-001 (dose equivalent
to 0.5 μg/ml and 1.5 μg/ml of Spirulina) for 48 h. Then, MMP, PGE2, collagen and scleraxis expression was evaluated by RT-PCR (a and c) or ELISA
(b). Histograms represent mean values from 3 independent experiments ± SEM
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tendon cells, including inhibition of cell proliferation
(data not shown), increased expression of p65 NFkB
subunits and MMPs (at least at mRNA level). However,
unlike others works [42, 43], we did not observe a
reduction of matrix genes.
The second model consisted to treat monolayer cell
cultures with IL-1β [44]. Indeed, pro-inflammatory cyto-
kines such as IL-1β have been identified as the main ini-
tiators of tendinopathy, stimulating inflammation,
apoptosis and matrix degradation [45]. At a tendon in-
jury site, pro-inflammatory cytokines such as IL-1β may
initiate a cascade of events leading to tendon destruction
and loss of biomechanical structural integrity. Further-
more, besides the up-regulation of inflammatory media-
tors (PGE2), we found that IL-1β significantly up-
regulates MMPs, and down-regulates the expression of
type I collagen whereas it increases type III collagen
mRNA in tendon cells. These modifications of matrix
gene expression are coherent with changes of tissue re-
modeling observed during TPs. Indeed, whereas normal
tendons mainly comprise type I collagen, injured ten-
dons have a higher percentage of type III collagen, which
is deficient in the number of cross-links between and
within the tropocollagen units [46]. Surprisingly, we did
not observe an increased expression of p65 mRNA after
IL-1β treatment. However, it is possible that the IL-1β
dose or treatment time was inadequate to observe NFkB
activation. Indeed, it is well known that IL-1β acts very
quickly on NFkB pathway (about minutes). However,
here, we analysed effects of IL-1β on tendon cells after
48 h-treatments. It may be too long [47]. Beside, here,
we used a single concentration of IL-1β (1 ng/ml)
whereas in the majority of previous study showing NFkB
activation in tenocytes, IL-1β was used at higher concen-
tration [48–50]. So, we may observe an effect whether
we had studied higher dose of IL-1β, or used a shorter
incubation time. In addition, we could not exclude that,
in tenocytes, IL-1β induces NFκB activation through a
post-transcriptional regulation. Indeed, NF-κB is present in
the cytoplasm in its resting stage as a heterotrimer complex
consisting of two subunits and an additional inhibitory sub-
unit, IκBα [51]. During the activation process, the inhibitory
subunit IκBα is phosphorylated at Ser-32 and Ser-36
residues by IKK kinase (IκBα kinase) and is subsequently
degraded. Once released, subunits of activated NF-κB trans-
locate to the nucleus and mediate transcription of various
inflammatory and catabolic gene products [52, 53]. Thus, it
is likely that IL-1β induces NF-κB activation in tenocytes
[44], whereas it does not upregulate p65 mRNA expression,
and consequently by a different mechanism than CIP. IL-1β
may also act through the activation of numerous other
signal transduction systems such as MAP kinases.
Although CIP and IL-1β have been several times used
in tenocytes [42, 43, 54, 55], this is, at our knowledge,
the first report comparing their effects. This work shows
that CIP has moderate effects on tendon cells, compared
to IL-1β, suggesting that IL-1β treatment is a better
model to mimic tendinopathies in vitro (with an increase
of MMPs, PGE2 and type III collagen expression) than
CIP. However, a CIP treatment may also be used to
mimic fluroquinone-induced TP.
Next, we used these both treatments to investigate the ef-
fect of a nutraceutical formulation composed mainly of
Spirulina (TOL19-001®) on tendon cells. We found that
TOL19-001® reduces the expression of MMPs, PGE2 and
type III collagen in IL-1β stimulated cells. In addition, in
CIP-treated cells, TOL19-001® decreases MMP2 and p65
mRNA expression, whereas it increases one of TIMP1. This
data suggest that TOL19-001® may be benefit for patients
suffering of tendinopathies.
The downregulation of PGE2, which is present at high
levels in injured tendons and causes vasodilatation [56]
and hyperalgesia [57], may reduce pain associated with
tendon inflammation. Indeed, PGE2 can increase the
amount of substance P, a major neuro-transmitter of
pain sensations which is released in sensory nerves [58].
Fig. 6 Effect of TOL19-001® in CIP stimulated-tendon cells. Tendon cells have been treated with CIP (100 μg/ml) and TOL19-001 (dose equivalent
to 0.5 μg/ml and 1.5 μg/ml of Spirulina) for 48 h. Then, MMP2, TIMP1 and p65 mRNA expression was evaluated by RT-PCR. Histograms represent
mean values from 3 independent experiments ± SEM
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Furthermore, healing tendons eventually form type III
collagen-rich scar tissue, which impairs tendon function
and makes the tendon susceptible to re-injury because
the scar tissue has inferior mechanical properties com-
pared to intact tendons (rich in type I collagen) [59]. In
these conditions, TOL19-001® may have a benefit effect
on healing in reducing type III collagen production.
Besides, TOL19-001® reduces expression of MMPs,
which may reduce the deterioration of tendons. Indeed,
matrix metalloproteinases are known to be involved in
tendon matrix degradation [60, 61] due to their ability to
degrade various ECM components, including collagen,
fibronectin, and proteoglycans [62]. MMPs are expressed
in normal tendon and upregulated during tendon healing
[63, 64]. Given their role in the degradation and remodel-
ing of tissue, we hypothesize that the inhibition of MMP
expression induced by TOL19-001® might favor regenera-
tive processes and tendon scarring.
TOL19-001® is mainly composed of Spirulina (S. max-
ima) (about 60 %), glucosamine sulfate (~20 %), and gin-
seng (~15 %). Consequently, it is difficult to know which
component is responsive for TOL19-001® action. Spirulina
(Arthrospira) maxima, is an undifferentiated multicellular
filamentous cyanobacterium (blue-green alga) [65] that has
a long history of use as food. Early interest in Spirulina
focused mainly on its potential as a source of protein and
vitamins [65, 66], but recently more attention has been
made to study its therapeutic use, and a number of pub-
lished reports suggest beneficial effects of this microalgae.
Spirulina have anti-cancer and immune suppressing
actions [67–69], antioxidant properties [70] and anti-
inflammatory activity [71–73]. Antioxidant properties of
this cyanobacterium are attributed to molecules, such as
c-phycocyanin, β-carotene, tocopherol, γ-linolenic acid,
and phenolic compounds. The c-phycocyanin from Spiru-
lina has been shown to exert strong free radical scavenging
activity [74]. Studies in vitro and in vivo have shown that
the antioxidant components produced by Spirulina [65,
75] can prevent or delay oxidative damage by reducing the
accumulation of ROS [76] through the activation of the
antioxidant enzyme systems of catalase (CAT), superoxide
dismutase (SOD), and glutathione peroxidase (GPx) [77].
Besides, the anti-inflammatory activity of phycocyanin has
been demonstrated in various in vitro studies and in vivo
experimental models such as mice with arthritis or sepsis
[78–80]. In addition to Spirulina, glucosamine sulfate may
also be responsive for anti-inflammatory effects of TOL19-
001® in tendon cells.
Conclusions
Tendon injuries are a common condition encountered
in orthopaedic surgery and sport medicine practice. In
the past few decades, incidences of tendon injuries have
increased significantly in both recreational and highly-
competitive athletes. NSAID are insufficient for treat
tendinopathies due to their numerous side effects. Here,
thanks to the characterization of in vitro models using
tendon cells cultured in monolayer to study TP, we show
that diet supplementary enriched in Spirulina and
glucosamine sulfate, such as TOL19-001®, may be ben-
efic against TP by regulating inflammation and tendon
matrix remodeling.
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